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Summary: By developing a quantitative integrative approach combining phylogenetic, virological, 
behavioral, and STI data, we identified changing drivers of ongoing HIV transmission among MSM 
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ABSTRACT  
Background. Identifying local outbreaks and their drivers is a key step towards curbing HIV 
transmission and potentially achieving HIV elimination. Such outbreaks can be identified as 
transmission clusters extracted from phylogenetic trees constructed of densely sampled viral 
sequences. In this study, we combined phylogenetic transmission clusters with extensive data on 
virological suppression and behavioral risk of cluster members to quantify the drivers of ongoing 
transmission over ten years. 
Methods. Using the comprehensive Swiss HIV Cohort Study and its drug-resistance database, we 
reconstructed phylogenetic trees for each year between 2007-2017. We identified HIV transmission 
clusters dominated by men who have sex with men(MSM) and determined their annual growth. We 
used Poisson regression to assess if cluster-growth was associated with a per-cluster-infectivity and 
behavioral-risk score.  
Results. Both infectivity and behavioral risk scores were significantly higher in growing MSM 
transmission clusters compared to non-growing clusters (p≤0.01). The fraction of transmission clusters 
without infectious members acquiring new infections increased significantly over the study period. 
The infectivity score was significantly associated with per-capita incidence of MSM transmission 
clusters in eight years, while the behavioral risk score was significantly associated with per-capita 
incidence of MSM transmission clusters in three years. 
Conclusions. We present a phylogenetic method to identify hotspots of ongoing transmission among 
MSM. Our results demonstrate the effectiveness of treatment as prevention at the population level. 
However, the significantly increasing number of new infections among transmission clusters without 
infectious members highlight a relative shift from diagnosed to undiagnosed individuals as drivers of  
HIV transmission in Swiss MSM. 
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INTRODUCTION 
The global epidemic of human immunodeficiency virus (HIV) is still not under control with 
approximately 1.7 million new HIV infections in 2018 [1]. As the HIV community embraces the UNAIDS 
90-90-90 targets for HIV diagnosis, treatment and viral suppression, the focus has largely been on 
increasing access to antiretroviral treatment (ART) [2]. However, reducing HIV incidence remains a 
mains challenge in HIV medicine. Thus, optimizing prevention using state-of-the-art methodology and 
allocating resources for prevention to subpopulations at risk are crucial to curbing the epidemic.  
Molecular epidemiology is essential for the improvement of prevention of new HIV infections [3,4]. 
The possibilities of molecular epidemiology have advanced with increasing computational power and 
availability of densely sampled HIV sequencing data from genotypic resistance testing (GRT). 
Representative HIV phylogenies can be reconstructed to subsequently extract phylogenetic clusters. 
Epidemiologically, these phylogenetic clusters reflect transmission chains that are or were ongoing 
and can identify local outbreaks within epidemics. Subgroups within the epidemic with a higher risk 
of leading to local outbreaks may be identified by specific clinical, demographic, or behavioral factors 
[5–9]. This study presents a new longitudinal method of identifying HIV clusters at risk of transmission, 
combining molecular epidemiology tools with classical clinical and behavioral risk factors. Our method 
was applied to men who have sex with men (MSM) enrolled in the Swiss HIV Cohort Study (SHCS) as a 
case study. 
Within the SHCS it has been shown that more than half of Swiss HIV infected individuals were included 
in transmission clusters and that most of these individuals were infected via the same transmission 
route [10]. MSM having unprotected anal sex represent the major risk group for ongoing transmission 
of HIV in Western Europe and North America [11]. Based on numbers of newly diagnosed cases over 
the last decade, the epidemic in MSM does not seem to be under control [12]. Recent studies in this 
community indicate reduced condom use in some subgroups of MSM [9,13,14]. Additionally, the 
numbers of HIV-positive MSM infected with sexually transmitted infections (STI), such as Syphilis, 
Chlamydia, and Hepatitis C, have been on the rise in the past decade [15–19]. 
In 2011 global HIV-prevention efforts progressed considerably when the HPTN 052 trial demonstrated 
that ART reduces the sexual transmission of HIV in HIV-serodiscordant couples by more than 96% [20]. 
In MSM the risk of HIV transmission through condom-less sex when the HIV viral load is suppressed 
was recently shown to be effectively zero (upper 95% confidence interval of 0.23 per 100 couple-years 
of follow-up) [21] thereby confirming the concept of treatment as prevention (TasP) on the individual 
level for MSM. The impact of TasP at the population level is less clear. The results of the HPTN 071 
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incidence [22]. In Switzerland, TasP was gradually introduced after  2008 based on  the Swiss 
statement [23]. What still remains controversial about TasP is its impact on risk behavior of HIV-
positive individuals potentially compensating effects of TasP by increasing risk behavior [16]. Utilizing 
the comprehensive database of the SHCS we sought to better understand impacts of TasP and the 




The Swiss HIV Cohort Study 
The SHCS is a large, prospective, multi-center study established in 1988 [24]. At each semi-annual 
follow-up visit clinical and laboratory data of three-monthly visits are obtained from SHCS participants. 
The SHCS has an estimated coverage of approximately 75% of all HIV-positive individuals on ART [24] 
in Switzerland. It includes a drug resistance database that contains HIV sequences for approximately 
60% of the over 20,000 SHCS participants and 75% of all participants enrolled after 1995, because over 
11,000 genotypes were retrospectively sequenced from the SHCS biobank [25,26]. Written informed 
consent was obtained from each SHCS study participant. 
 
Phylogenetic Tree Construction 
For each of the years from 2007 to 2017, we considered all partial pol sequences of SHCS participants, 
which were available prior to the beginning of the respective year and had adequate quality (at least 
250 base pairs from protease and at least 500 base pairs from reverse transcriptase). If multiple 
sequences per patient were available, the first one was considered. Importantly, all sequences 
included in a certain year were also included in subsequent years. For each year, we blasted non-Swiss 
Los Alamos background sequences  against the described choice of SHCS sequences (targeting the 10 
closest sequences with a threshold of 90%). SHCS and Los Alamos sequences were pooled and pairwise 
aligned to the HXB2 reference genome using MUSCLE [27]. Insertions relative to HXB2 and resistance 
mutations according to the Stanford (http://hivdb.stanford.edu/) and International Antiviral Society-
USA (https://www.iasusa.org/) lists were removed, and positions with many gaps were eliminated by 
trimAl [28]. Maximum likelihood phylogenetic trees were reconstructed with FastTree using a 
generalized time-reversible model [29]. We obtained eleven phylogenetic trees reflecting the 
observed transmission network within the SHCS in the beginning of each year from 2007 to 2017 
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Extraction of MSM transmission clusters 
We identified transmission clusters using phylogenetic tree topology including Los Alamos background 
sequences to split individual groups who were not closely related in the transmission chain into 
phylogenetic clades consisting of at least 80% SHCS sequences. As we aimed to study MSM 
transmission clusters, we discarded transmission clusters if they did not consist of at least 50% Swiss 
MSM. This definition allowed to also capture transmission clusters that did not exclusively contain 
MSM, which is especially of important considering MSM who did not disclose as MSM and women 
infected by bisexual men. We did not consider newly emerging clusters since we were interested in 
the predictive power of the clusters that already existed the year before. Therefore, we defined 
“preexistent” clusters as clusters that existed in the previous year containing at least 50% of the 
already infected members appearing in MSM transmission clusters (Figure 1). Transmission clusters 
were extracted using custom scripts incorporating the R package APE [30]. 
 
Identification of newly infected MSM  
For each study year, we identified all MSM in the SHCS who were newly infected in that year and 
reported to have been infected in Switzerland (thus for the new infections considered, we excluded 
MSM reporting to have been infected abroad. This information is only collected in the SHCS since 
2007, thus, we did not consider earlier years). The time period spanned the first to  the last day of the 
year (i.e., newly infected MSM in 2016 were infected between 2016-01-01 and 2016-12-31). MSM 
were considered newly infected in a certain year, if they had both (i) their first GRT done within the 
year and (ii) their estimated date of infection (EDI) was within the year (MSM with first GRT and EDI 
in different years were discarded as newly infected). 
We used the following two methods to estimate HIV infection dates as accurately as possible: 
(1) Defined HIV primary infection: For individuals with available seroconversion dates (negative and 
positive HIV tests less than 1 year apart) or with a diagnosis of primary infection as previously 
described [31], we used the midpoint between the dates of the negative and the positive test, or, if 
known, the date of the primary infection as best estimate of the HIV infection date. 
(2) Defined recent HIV infection: For individuals who (i) exhibited low HIV diversity (less than 0.5% of 
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and (ii) had >200 CD4+ cells/µl blood at cohort registration [32–34], we used the diagnosis date as 
best estimate of the HIV infection date. 
Individuals for whom neither (1) nor (2) was possible to estimate the date of infection, were viewed 
as not newly infected within that given year and thus excluded from analysis (i.e. newly diagnosed 
chronic infections were excluded from our analysis).  
 
Definition of explanatory variables 
For each MSM transmission cluster and each considered calendar year, we calculated the following 
explanatory variables using all individuals within the transmission clusters (not only those who 
disclosed as MSM). 
Annual infectivity score: For each MSM transmission cluster, the infectivity score is defined as the 
fraction of cluster members who had at least one viral load greater than 1,000 copies in the year of 
interest. Laboratory values such as the viral load are usually measured during every quarterly to half 
yearly follow-up visit for individuals participating in the SHCS. 
Annual behavioral risk score: For each MSM transmission cluster, the behavioral risk score is defined 
as the fraction of cluster members who either reported risky behavior and/or had a coinfection with 
Hepatitis B, C or Syphilis (Figure 3d) as a surrogate for risky behavior. Risky behavior was defined as 
reported condom-less anal or vaginal intercourse with occasional partners or refusal to answer this 
question (on median 3 participants per year refused an answer, IQR=[2,5]). A Hepatitis B coinfection 
was present if both the qualitative result of an Anti-HBc-test and the qualitative result of an HBsAg-
test were positive. A Hepatitis C coinfection was present if either the qualitative result of an Anti-HCV-
test was positive or Hepatitis C RNA viral load from a quantitative test was detectable. A Syphilis 
coinfection was present if the qualitative result of the screening test and the interpretation of the 
quantitative result were positive. Coinfections were primarily included as proxies for risk behavior [19] 
and not because we assumed that they biologically facilitate HIV-transmission. 
 
Statistical Analysis 
Regression analysis: In order to evaluate the infectivity and behavioral risk score as predictors for new 
infections, we performed multivariable Poisson regression analyses using behavioral risk score and 
infectivity score as predictor variables. For each study year, we identified pre-existing clusters from 
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newly infected MSM within each cluster. We then used the number of new infections within each 
cluster as an outcome variable and included infectivity and behavioral risk score of each cluster from 
the previous year as predictor variables. By separating predictor and outcome variables by time we 
aimed at establishing a causal relationship (i.e. to test that the former cause the latter). Further, we 
included the logarithm of the number of cluster members as an offset to exclude the risk of observing 
an effect driven by the higher chance of acquisition of newly infected MSM in larger MSM transmission 
clusters. Thus, we model the numbers of new infections per cluster as  
𝑁𝑛𝑒𝑤~𝑃𝑜𝑖𝑠𝑠(𝜆(𝑁, 𝑅𝑖𝑠𝑘𝑆𝑐𝑜𝑟𝑒, 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑆𝑐𝑜𝑟𝑒)) 
Where  
𝜆(𝑁, 𝑅𝑖𝑠𝑘𝑆𝑐𝑜𝑟𝑒, 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑆𝑐𝑜𝑟𝑒) = 𝑒log(𝑁)+𝑎0+𝑎1RiskScore+𝑎1InfectivityScore 
= 𝑁𝑟(𝑅𝑖𝑠𝑘𝑆𝑐𝑜𝑟𝑒, 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑆𝑐𝑜𝑟𝑒) 
and thus  
𝑟(𝑅𝑖𝑠𝑘𝑆𝑐𝑜𝑟𝑒, 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑆𝑐𝑜𝑟𝑒) = 𝑒𝑎0+𝑎1RiskScore+𝑎1InfectivityScore  
is the per capita growth rate of the clusters. Accordingly, the exponential of the coefficients derived 
from the poisson regression analysis can be interpreted as the effect from the risk and the infectivity 
scores on the per capita cluster growth rate of the considered transmission  clusters. In other words, 
these coefficients can be interpreted as the per capita incidence risk ratios.  
 
P-values for differences and time trends: P-values for time trends over our study period were derived 




Study population of MSM within MSM transmission clusters 
Table 1 displays characteristics of MSM within MSM transmission clusters and of all non-clustered 
MSM on the respective phylogeny for the first and last study year (Table S1 for all study years). Of the 
individuals in the MSM transmission clusters at least 77.9% were MSM, while up to 9.5% of individuals 
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Incidence of newly infected MSM within MSM transmission cluster during 10-year study period 
The annual number of newly infected MSM, identified by incorporating estimated infection dates and 
excluding new diagnosis of chronic infections (see Methods), decreased significantly over our study 
period (ptrend < 0.001, Figure 2a). Between 30.61% (2009) and 57.14% (2014) of the newly infected 
MSM appeared within preexistent MSM transmission clusters (ptrend = 0.802, Figure 2a). The majority 
of newly infected MSM not in preexisting MSM transmission clusters appeared in newly emerged 
clusters containing only two individuals including the newly infected MSM (Figure S2).  
 
Characteristics of MSM transmission clusters acquiring newly infected MSM 
The mean annual infectivity score for MSM transmission clusters significantly decreased over the 
study period (Figure 3a). This paralleled the observation that the median time between HIV diagnosis 
to treatment initiation decreased from a maximum of 22 weeks in 2008 to a minimum of 3 weeks in 
2016 (Figure S3), indicating a decreasing fraction of infectious SHCS participants over our study period. 
In contrast, the mean annual behavioral risk score for MSM transmission clusters strongly increased 
over the study period (Figure 3b). Both the infectivity and the behavioral risk score were significantly 
higher in MSM transmission clusters that acquired newly infected MSM, compared to MSM 
transmission clusters not acquiring newly infected MSM (pdifference < 0.001 each, Figure 3a&b). The 
fraction of transmission clusters acquiring new infections, even though not containing any infectious 
members (i.e., infectivity score of 0), increased significantly over the study period (ptrend = 0.017, Figure 
3c), reaching levels of up to 50% by 2016.  
 
Per capita cluster growth was determined by annual infectivity and behavioral risk scores  
Multivariable Poisson regression analysis revealed that the annual infectivity score was significantly 
and independently associated with per capita cluster growth of MSM transmission clusters in 8 out of 
10 study years (2007-2011, 2013-2014, 2016) (Figure 4). At the same time, the annual behavioral risk 
score was significantly associated with the per capita MSM transmission clusters growth in 3 out of 10 
study years (2011-2012, 2014). Combining the two scores did not improve the observed associations 
(Table S2). These associations highlight the potential of identifying transmission clusters at high risk 
of transmission using these already available variables. At the same time, our power to predict cluster 
growth in the subsequent year using the previous regression analysis decreased strongly over our 










This is the first study quantifying the risk of ongoing transmission in phylogenetically identified clusters 
by combining data on virological suppression with behavioral risk thereby identifying the changing 
drivers of the HIV epidemic. Based on the comprehensive SHCS, this analysis was performed for over 
a decade and thus provides a long-term perspective on challenges underlying HIV elimination. The 
decreasing infectivity score along with the decreasing total number of newly infected MSM over the 
study period provide evidence for a beneficial effect of TasP at the population level. Despite the 
increase of the behavioral risk score in the last years of our study period HIV-infections still decreased, 
illustrating that TasP also works in the context of risky behavior. Over one decade, we found a 
significantly increasing fraction of transmission clusters which acquired new infections but did not 
contain any infectious members. In particular, in the last study years up to one half of MSM 
transmission clusters acquiring newly infected MSM contained only virally suppressed cluster 
members. Given the proven effectiveness of TasP at the individual level [20,21,35], this implies that 
there were unsampled or undiagnosed HIV-positive individuals within the transmission networks 
corresponding to the MSM transmission clusters we identified. This is additionally supported by our 
finding of a significantly decreasing power to predict cluster growth over our study period and 
illustrates the declining role of people living with diagnosed but unsuppressed HIV in driving the more 
recent epidemic. Furthermore, this highlights that in recent years a relative shift occurred from the 
diagnosed to the undiagnosed population as the driver of the HIV epidemic in Swiss MSM.  
Our study has limitations and strengths. As any study in molecular epidemiology, we cannot achieve 
perfect sampling. Even though the SHCS is highly representative of the HIV epidemic in Swiss MSM, 
phylogenetically identified transmission clusters are likely to have unsampled members. Thus, the 
detected transmission clusters should be interpreted as proxies for the actual transmission networks. 
However, despite the incomplete sampling, our approach allows for relevant conclusions about the 
drivers of the epidemic. In particular, in the last study years we observed newly infected individuals in 
clusters where all members were virally suppressed, implying that there were 
unsampled/undiagnosed HIV-positive individuals within the transmission networks of the 
corresponding MSM transmission clusters. Further, the estimated dates of infection sometimes 
harbor large confidence intervals. Thus, we may not exclude the possibility of incorrectly categorizing 
individuals as “newly infected”. However, the quality of our estimated infection dates using defined 
HIV primary or recent infections was not time-dependent (data not shown) and misclassification of 
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over the time period examined. These shortcomings are therefore unlikely to explain any of the 
observed outcomes. Further, there is no consensus or gold-standard for phylogenetically defining HIV 
transmission clusters. The frequently used cluster detection methods fall into three categories: 
distance-based, topology-based or a combination of the two. Suitability of the methods highly 
depends on the research question of interest. In our case, a distance-based approach was not suitable 
since we did not want to prioritize new infections within recently established compared to long-
circulating transmission clusters – thus, we applied a purely topological approach.  The strengths of 
this study include that the statistical analysis directly yields the impact of risk and infectivity scores on 
the observed per-capita growth rate of the cluster over a long-term perspective in a representative 
population.  
We demonstrate a new method to track the epidemiology of HIV, thereby identifying hotspots of 
ongoing transmission among MSM. The identified high-risk clusters could be used to target social 
networks harboring undiagnosed individuals spreading HIV. In these social networks, intensification 
of prevention (e.g. testing campaigns and PrEP) is likely to have the largest impact. The significantly 
increasing number of new infections within transmission clusters without infectious members, 
indicates a relative shift of epidemiological importance from diagnosed to undiagnosed individuals as 
drivers of the epidemic. Further, this highlights the need for additional efforts to identify infectious 
individuals as early as possible and to link them into care. Our method, combining phylogenetics, 
clinical and behavioral data, sheds light on high risk social networks, where prevention and HIV-testing 
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1767 1124 - 785 - 
median age (IQR) 
45 (40,52) 45 (40,54) 0.091 49 (43,58) 
<0.00
1 
white ethnicity (%) 
95.59% 92.45% <0.001 93% 0.51 
median CD4 cell count at 
diagnosis (IQR) 
367 
(196.5,557) 345 (184,537) 0.065 290 (115,487) 
<0.00
1 
median year of SHCS 
registration (IQR) 
1998 
(1994,2003) 1998 (1994,2003) 0.5 1995 (1992,2000) 
<0.00
1 
      
year 2017      
N 
3429 1544 - 1372 - 
median age (IQR) 
51 (44,58) 52 (43,60) 0.056 53 (45,63) 0.003 
white ethnicity (%) 
92.97% 86.69% <0.001 88.63% 0.104 
median CD4 cell count at 
diagnosis (IQR) 
381.5 
(222,561) 367.5 (200,546.5) 0.03 
369.5 
(194,577.25) 0.735 
median year of SHCS 
registration (IQR) 
2005 




Table 1. Individuals’ characteristics in the first (2007) and the last (2017) year of the study. MSM 
transmission clusters were defined as phylogenetic transmission clusters consisting of at least 50% 
MSM. The first column “MSM in clusters” refers to MSM cluster members, the second column “non-
clustered MSM on tree” refers to all MSM who were on the respective phylogeny (i.e. with an available 
GRT), while the column “MSM not on phylogeny” includes all MSM registered in the SHCS but not on 
the phylogeny (i.e., individuals without sequencing data) with follow-up data after the beginning of 
the year 1995, when the collection of plasma samples was initiated. P-values comparing characteristics 
of MSM in clusters to non-clustered MSM on the tree and all MSM included in the analysis to all MSM 
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Figure legends 
Figure 1. Methods overview. For all pairs of two consecutive years (year x and year x+1, x being one 
of the years from 2007 to 2016) phylogenetic trees were built of sequences available prior to the 
respective years (green tips refer to MSM transmission clusters, blue tips refer to all other). We 
extracted MSM transmission clusters from these phylogenetic trees and checked which MSM 
transmission clusters were preexistent in the previous year with at least 50% of the already infected 
members in MSM transmission clusters. For all preexisting clusters, we calculated the number of newly 
infected MSM hat were acquired by the respective cluster within the year of interest. Further, we 
assigned a behavioral risk and an infectivity score to each preexistent cluster of year x. We performed 
a regression analysis to investigate the association of behavioral risk and infectivity score and the 
number of newly infected individuals with MSM transmission clusters (indicated by question mark). 
 
Figure 2. Newly infected MSM within MSM transmission clusters. (a) Number of newly infected MSM 
with acute or recent HIV-infection (as defined in the Methods section, solid green line) and fraction of 
all newly infected MSM who appear within preexisting phylogenetic MSM transmission clusters (as 
defined in the Methods section, dashed pink line). P-values for time trends were derived using linear 
regression. (b) Example of 3 MSM transmission clusters acquiring newly infected MSM between 2007-
01-01 and 2008-01-01. Olive green color represents individuals who were already in the cluster in the 
previous year, pink newly infected individuals within the cluster, black Los Alamos background 
sequences and light green other SHCS participants (SHCS participants who were not in the same cluster 
in the previous year). 
 
Figure 3. Characteristics of MSM transmission clusters acquiring newly infected individuals. The x-
axis denotes the study year (first year per tick: year of transmission clusters used to identify cluster 
characteristics; second year per tick: year of transmission clusters used to identify cluster growth). (a) 
Mean annual per-cluster infectivity scores of clusters acquiring newly infected individuals (squares) 
compared to clusters not acquiring newly infected individuals (circles). The fraction of cluster members 
who were infectious (defined as at least one viral load ≥ 1’000 copies/ml) within the study years 
displayed on the y-axis. (b) Mean annual per cluster behavioral risk scores of clusters acquiring newly 
infected individuals (squares) compared to clusters not acquiring newly infected individuals (circles). 
The fraction of cluster member who either reported risk-behavior and/or had a coinfection (Hepatitis 
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risk scores of zero. The fraction of clusters acquiring newly infected individuals even though harboring 
an infectivity (green) or behavioral risk score (pink) of zero is displayed on the y-axis. Total number of 
clusters identified at the beginning of the first year per tick (“clusters”) and number of clusters 
acquiring newly infected MSM during the next year (“growing”) are displayed. P-values for time trends 
were derived using linear regression. P-values for differences were derived using paired Wilcoxon rank 
sum test. 
 
Figure 4. Association of cluster infectivity and cluster risk behavior with per capita cluster growth.  
Results of a Poisson regression with per capita growth as outcome, and infectivity as well as behavioral 
risk score as dependent variables. The effect of (a) the infectivity score and (b) the behavioral risk score 
on the incidence rate ratio is depicted on the y-axis, while the x-axis shows the study years. Coefficients 
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